In Parkinson's disease, current predominant treatment with intermittent oral administration of levodopa (l-dopa) remains the reference standard, but it has pharmacological drawbacks that trigger motor fluctuati
Parkinson’s disease is a neurodegenerative disease caused by the death of neurons, ie, cells critical to the production of dopamine, an important neurotransmitter in the brain. Here, we present a brief review of the dopamine synthetic pathway, binding to the dopamine receptors, and subsequent act...
Although striatal delivery of three critical genes for dopamine synthesis by viruses is a potential clinical approach for treating Parkinson’s disease (PD), the approach makes it difficult to finely control dopamine secretion amounts and brings safety c
Although dopamine receptor agonists are not simple to use, they are assuming increased importance in the treatment of early and advanced symptoms of Parkinson’s disease (PD). The new agonists, pramipexole and ropinirole, are generally adequate without levodopa for early symptoms and carry the hope ...
A. A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinsonas disease. Cell Rep. 2, 1747–1761 (2012). Article PubMed PubMed Central CAS Google Scholar Wise, R. A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 5, 483–494 (2004). Article Pub...
Recently the therapeutic approach to Parkinson鈥檚 disease has begun to change and the role of dopamine agonists become more prominent especially in early treatment (i.e. in patients who have not previously received any other dopaminergic treatment for Parkinson鈥檚 disease). There are now ...
Koller, W CRope, S DHuber, S JBlumenthal, D CBlumenthal, H J
Dopamine agonists in Parkinson's disease. Can J Neurol Sci. 1984 Feb; 11 (1 Suppl):221–224. [ PubMed ]Lieberman AN, Gopinathan G, Neophytides A, Nelson J, Goldstein M. Dopamine agonists in Parkinson's disease. In: Stern G, editor. London (UK): Chapman and Hall; 1990. p. 509-...
Clinical studies of Parkinson's disease (PD) using a dopamine cell replacment strategy have been tried for more than 30 years. The outcomes following transplantation of human fetal ventral mesencephalic tissue (hfVM) have been variable, with some patients coming off their anti-PD treatment for ...
Connolly BS, Lang AE . Pharmacological treatment of Parkinson disease: a review.: 1670–1683. Acknowledgements et al., and a grant from the Network Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED) that supports the work of Takahashi...